DiscoveRx Corporation And BioFocus DPI Announce a Co-Marketing Agreement for GPCR Screening

FREMONT, Calif.--(BUSINESS WIRE)--DiscoveRx Corp. and BioFocus® announced today that they have signed a co-marketing agreement that allows BioFocus to perform screening on behalf of BioFocus’ customers using DiscoveRx PathHunter™ ß-Arrestin GPCR screening assay, HitHunter™ cAMP assays and associated cell lines.

MORE ON THIS TOPIC